Tumor lysis syndrome after induction chemotherapy in small-cell lung carcinoma.

Abstract

Small-cell lung cancer (SCLC) is responsive to combination chemotherapy. Response rates of 50-80% can be achieved depending on whether the cancer is limited or extensive. Rarely, patients with SCLC respond so rapidly to induction chemotherapy that they develop a tumor lysis syndrome. This syndrome may lead to azotemia and renal failure if not recognized… (More)

Topics

  • Presentations referencing similar topics